Cancer incidence in systemic sclerosis: Meta-analysis of population-based cohort studies

Arthritis and Rheumatism

Volumn 65, Issue 7, 2013, Pages 1913-1921

  Onishi, Akira ^a   Sugiyama, Daisuke ^b   Kumagai, Shunichi ^a   Morinobu, Akio ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUSTRALIA; BLADDER CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CINAHL; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DATA EXTRACTION; DENMARK; FOLLOW UP; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LEUKEMIA; LIVER CANCER; LUNG CANCER; MEDICAL SUBJECT HEADINGS; MEDLINE; META ANALYSIS; NON MELANOMA SKIN CANCER; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; POPULATION SIZE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY CONTROL; STANDARDIZED INCIDENCE RATIO; STUDY DESIGN; SWEDEN; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; TAIWAN; UNITED KINGDOM; UNITED STATES; UTERINE CERVIX CANCER; UTERUS CANCER;

COHORT STUDIES; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; INCIDENCE; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; SCLERODERMA, SYSTEMIC; SEX DISTRIBUTION; URINARY BLADDER NEOPLASMS;

EID: 84879848593     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37969     Document Type: Article

References (50)

1. Abraham DJ, Krieg T, Distler J, Distler O,. Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 2009; 48 Suppl 3: iii3-7.
2. Ranque B, Mouthon L,. Geoepidemiology of systemic sclerosis. Autoimmun Rev 2010; 9: A311-8.
3. Smitten AL, Simon TA, Hochberg MC, Suissa S,. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008; 10: R45.
4. Zahr ZA, Baer AN,. Malignancy in myositis. Curr Rheumatol Rep 2011; 13: 208-15.
5. Zintzaras E, Voulgarelis M, Moutsopoulos HM,. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005; 165: 2337-44.
6. Rosenthal AK, McLaughlin JK, Gridley G, Nyren O,. Incidence of cancer among patients with systemic sclerosis. Cancer 1995; 76: 910-4.
7. Derk CT, Rasheed M, Artlett CM, Jimenez SA,. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006; 33: 1113-6.
8. Abu-Shakra M, Guillemin F, Lee P,. Cancer in systemic sclerosis. Arthritis Rheum 1993; 36: 460-4.
9. Duncan SC, Winkelmann RK,. Cancer and scleroderma. Arch Dermatol 1979; 115: 950-5.
10. Olesen AB, Svaerke C, Farkas DK, Sorensen HT,. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol 2010; 163: 800-6.
11. Kang KY, Yim HW, Kim IJ, Yoon JU, Ju JH, Kim HY, et al. Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre. Scand J Rheumatol 2009; 38: 299-303.
12. Chatterjee S, Dombi GW, Severson RK, Mayes MD,. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 2005; 52: 2415-24.
13. Thomas E, Brewster DH, Black RJ, Macfarlane GJ,. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000; 88: 497-502.
14. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al, for the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000; 283: 2008-12.
15. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, and the STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies [published erratum appear in Ann Intern Med 2008;148:168]. Ann Intern Med 2007; 147: 573-7.
16. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988; 15: 202-5.
17. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D,. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59: 1690-7.
18. Buitrago-Lopez A, Sanderson J, Johnson L, Warnakula S, Wood A, Di Angelantonio E, et al. Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis. BMJ 2011; 343: d4488.
19. Wong WC, Cheung CS, Hart GJ,. Development of a quality assessment tool for systematic reviews of observational studies (QATSO) of HIV prevalence in men having sex with men and associated risk behaviours. Emerg Themes Epidemiol 2008; 5: 23.
20. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
21. Egger M, Smith GD, Altman DG, editors. Systematic reviews in health care: meta-analysis in context. 2nd ed. London: BMJ PublishingGroup; 2001.
22. Analyzing data and undertaking meta-analysis. In: Higgins JP, Green S (editors). Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration, 2011. URL: www.cochrane-handbook.org.
23. Hill CL, Nguyen AM, Roder D, Roberts-Thomson P,. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003; 62: 728-31.
24. Kuo CF, Luo SF, Yu KH, Chou IJ, Tseng WY, Chang HC, et al. Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol 2012; 41: 44-9.
25. Black KA, Zilko PJ, Dawkins RL, Armstrong BK, Mastaglia GL,. Cancer in connective tissue disease. Arthritis Rheum 1982; 25: 1130-3.
26. Roumm AD, Medsger TA Jr., Cancer and systemic sclerosis: an epidemiologic study. Arthritis Rheum 1985; 28: 1336-40.
27. Peters-Golden M, Wise RA, Hochberg M, Stevens MB, Wigley FM,. Incidence of lung cancer in systemic sclerosis. J Rheumatol 1985; 12: 1136-9.
28. Fuse Y, Masuyama J, Yoshio T, Mimori A, Takeda A, Minota S, et al. Progressive systemic sclerosis (PSS) and cancer-increasing coincidence rate of cancer in 67 PSS patients. Ryumachi 1995; 35: 25-31. In Japanese.
29. Higuchi M, Horiuchi T, Ishibashi N, Yoshizawa S, Niho Y, Nagasawa K,. Anticentromere antibody as a risk factor for cancer in patients with systemic sclerosis. Clin Rheumatol 2000; 19: 123-6.
30. Hashimoto A, Arinuma Y, Nagai T, Tanaka S, Matsui T, Tohma S, et al. Incidence and the risk factor of malignancy in Japanese patients with systemic sclerosis. Intern Med 2012; 51: 1683-8.
31. Pontifex EK, Hill CL, Roberts-Thomson P,. Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis 2007; 66: 551-3.
32. Wooten M,. Systemic sclerosis and malignancy: a review of the literature. South Med J 2008; 101: 59-62.
33. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
34. Hudson M, Lo E, Lu Y, Hercz D, Baron M, Steele R, the Canadian Scleroderma Research Group, et al. Cigarette smoking in patients with systemic sclerosis. Arthritis Rheum 2011; 63: 230-8.
35. Hissaria P, Roberts-Thomson PJ, Lester S, Ahern MJ, Smith MD, Walker JG,. Cigarette smoking in patients with systemic sclerosis reduces overall survival: comment on the article by Hudson et al [letter]. Arthritis Rheum 2011; 63: 1758-9.
36. Morton LM, Hartge P, Holford TR, Holly EA, Chiu BC, Vineis P, et al. Cigarette smoking and risk of non-Hodgkin lymphoma: a pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph). Cancer Epidemiol Biomarkers Prev 2005; 14: 925-33.
37. Castillo JJ, Dalia S, Shum H,. Meta-analysis of the association between cigarette smoking and incidence of Hodgkin's lymphoma. J Clin Oncol 2011; 29: 3900-6.
38. Yang Y, Fujita J, Tokuda M, Bandoh S, Ishida T,. Lung cancer associated with several connective tissue diseases: with a review of literature. Rheumatol Int 2001; 21: 106-11.
39. Assassi S, Fritzler MJ, Arnett FC, Norman GL, Shah KR, Gourh P, et al. Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol 2009; 36: 2250-6.
40. Cavazza A, Caballeria L, Floreani A, Farinati F, Bruguera M, Caroli D, et al. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology 2009; 50: 1162-8.
41. Centers for Disease Control and Prevention. Hepatocellular carcinoma-United States, 2001-2006. MMWR Morb Mortal Wkly Rep 2010; 59: 517-20.
42. Leone G, Pagano L, Ben-Yehuda D, Voso MT,. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007; 92: 1389-98.
43. Pan SF, Rodnan GP, Deutsch M, Wald N,. Chromosomal abnormalities in progressive systemic sclerosis (scleroderma) with consideration of radiation effects. J Lab Clin Med 1975; 86: 300-8.
44. Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124: 477-84.
45. Marasini B, Conciato L, Belloli L, Massarotti M,. Systemic sclerosis and cancer. Int J Immunopathol Pharmacol 2009; 22: 573-8.
46. Forbes AM, Woodrow JC, Verbov JL, Graham RM,. Carcinoma of breast and scleroderma: four further cases and a literature review. Br J Rheumatol 1989; 28: 65-9.
47. Hassett G, Harnett P, Manolios N,. Scleroderma in association with the use of docetaxel (taxotere) for breast cancer. Clin Exp Rheumatol 2001; 19: 197-200.
48. Pearson JE, Silman AJ,. Risk of cancer in patients with scleroderma. Ann Rheum Dis 2003; 62: 697-9.
49. Gadalla SM, Amr S, Langenberg P, Baumgarten M, Davidson WF, Schairer C, et al. Breast cancer risk in elderly women with systemic autoimmune rheumatic diseases: a population-based case-control study. Br J Cancer 2009; 100: 817-21.
50. Anderson LA, Gadalla S, Morton LM, Landgren O, Pfeiffer R, Warren JL, et al. Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer 2009; 125: 398-405.